文献速递流行病学与生物统计临床试验与 GCP

针对临床表现异质性罕见病、采用分层特异性终点与全局检验方法的新型临床试验设计

Novel Clinical Trial Design With Stratum-Specific Endpoints and Global Test Methods for Rare Diseases With Heterogeneous Clinical Manifestations.
PubMed 文献 · Stat Med · 2025-01-01

针对罕见病临床试验样本量有限、临床表现异质性强且难以预设统一主要疗效终点的问题,提出一种允许评估分层特异性疗效终点的新型试验设计,并开发多种非参数全局检验方法。以法布里病为例的模拟研究显示,采用全局检验方法评估该新型设计可能比所有患者使用相同终点的传统设计对治疗效应更敏感。

要点

  • 罕见病试验常因样本量有限而检验效能不足,且临床表现异质性使统一主要终点难以预设。
  • 提出允许在更广泛人群中评估分层特异性疗效终点的新型试验设计及非参数全局检验方法。
  • 法布里病模拟研究显示,新型设计结合全局检验可能比传统统一终点设计对治疗效应更敏感。

核心结论

  • 提出一种允许评估分层特异性疗效终点的新型试验设计及多种非参数全局检验方法,模拟研究显示该设计结合全局检验可能比所有患者使用相同终点的传统设计对治疗效应更敏感。

研究设计与样本

  • 方法学文章,提出新型试验设计与分析策略,并开发多种非参数全局检验方法;以法布里病患者为例开展模拟研究。

主要发现

  • 模拟研究示例显示,采用全局检验方法评估的新型设计可能比所有患者使用相同终点的传统设计对治疗效应更敏感。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many rare disease clinical trials are underpowered to detect a moderate treatment effect of an investigational product due to the limited number of participants available for the trials. In addition, given the complex, multisystemic nature of many rare diseases, it is challenging to confidently prespecify a single primary efficacy endpoint that is applicable to all trial participants with a heterogeneous clinical manifestation of their disease. Traditional trial designs and analysis methods often used in more common diseases to analyze the same endpoint(s) for all patients may be inefficient or impractical for a rare disease with heterogeneous clinical manifestations. To address these issues, we propose a novel trial design and analytic approach that allows for an evaluation of stratum-specific efficacy endpoints in a broader population of participants. We develop several nonparametric global test methods that can accommodate the novel design and provide global evaluation of treatment effects. Using a case example in patients with Fabry disease, our simulation studies illustrate that the novel design evaluated using the global test methods may be more sensitive to detect a treatment effect compared to the traditional design that uses the same endpoint(s) for all patients.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Shives E, Gurmu Y, Lee W, et al. Novel Clinical Trial Design With Stratum-Specific Endpoints and Global Test Methods for Rare Diseases With Heterogeneous Clinical Manifestations. Stat Med. 2025. PMID: 40772797. doi:10.1002/sim.70206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。